Evaluation of whole-blood clotting activity of recombinant factor IX Fc fusion protein by ROTEM analysis in a multi-centre Phase III clinical trial

被引：0
|
作者：
Sommer, Jurg M. [1 ]
Driessler, Frank [1 ]
Luk, Alvin [1 ]
Pierce, Glenn F. [1 ]
Jiang, Haiyan [1 ]
机构：
[1] Biogen Idec Hemophilia, Cambridge, MA USA
来源：
HAEMOPHILIA | 2014年 / 20卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：21 / 21
页数：1
相关论文
共 24 条
  • [1] Evaluation of whole blood clotting activity of recombinant factor VIII Fc fusion protein by ROTEM analysis in a multi-center Phase 3 clinical trial
    Sommer, J.
    Driessler, F.
    Miguelino, M.
    Powell, J.
    Luk, A.
    Pierce, G. F.
    Jiang, H.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2013, 11 : 39 - 39
  • [2] Evaluation of the thrombin generation potential of a recombinant factor IX Fc fusion protein (rFIXFc) in a phase 3 multi-national clinical trial
    Yang Buyue
    Jiang, Haiyan
    Luk, Alvin
    Pierce, Glenn F.
    Sommer, Jurg M.
    HAEMOPHILIA, 2014, 20 : 29 - 29
  • [3] Evaluation of the thrombin generation potential of a recombinant factor VIII Fc fusion protein (rFVIIIFc) in a phase III multi-national clinical trial
    Buyue, Y.
    Jiang, H.
    Luk, A.
    Pierce, G. F.
    Sommer, J.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2013, 11 : 228 - 228
  • [4] INTERNATIONAL ASSESSMENT OF RECOMBINANT FACTOR IX FC FUSION PROTEIN CLOTTING ACTIVITY AT VARIOUS HEMOPHILIA TREATMENT CENTERS
    Geske, F. Jon
    Sadeghi-Khomami, Ali
    AMERICAN JOURNAL OF HEMATOLOGY, 2016, 91 (09) : E411 - E412
  • [5] Assessment of recombinant factor IX-FC fusion protein (RFIXFC) clotting activity in plasma samples at canadian haemophilia treatment centres
    Geske, Jon F.
    Sadeghi-Khomami, A.
    Chaudhry, H. R.
    Sholzberg, M.
    Teitel, J.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2015, 13 : 316 - 316
  • [6] Factor IX activity measurement of recombinant FIX Fc fusion protein eftrenonacog alfa with one-stage clotting and chromogenic substrate assay
    Prudkova, Marie
    Chytra, Dagmar
    Smejkal, Petr
    Zavrelova, Jirina
    Kovarikova, Jana
    Penka, Miroslav
    Bulikova, Alena
    HAEMOPHILIA, 2024, 30 : 87 - 87
  • [7] Pharmacokinetic parameters of recombinant factor IX Fc fusion protein are not influenced by factor IX antigen levels in subjects from the Phase 3 B-LONG trial
    Sidonio Jr, Robert F.
    Casiano, Sandra
    Falk, Aletta
    Altincatal, Arman
    Katragadda, Suresh
    Santagostino, Elena
    Windyga, Jerzy
    HAEMOPHILIA, 2023, 29 (01) : 404 - 407
  • [8] Comparative field study evaluating the activity of recombinant Factor IX - Fc fusion protein (rFIXFc) in plasma samples at clinical haemostasis laboratories
    Sommer, J.
    Buyue, Y.
    Peters, R. T.
    Jiang, H.
    Gray, E.
    Pierce, G. F.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2013, 11 : 828 - 829
  • [9] Analysis of clinical target joint bleeding on prophylactic regimens with recombinant Factor IX Fc fusion protein in patients with severe hemophilia B
    Powell, Jerry S.
    Perry, David
    Baker, Ross I.
    Shapiro, Amy
    Manco-Johnson, Marilyn J.
    Potts, James
    Robinson, Brian
    Mei, Baisong
    Pierce, Glenn F.
    HAEMOPHILIA, 2014, 20 : 94 - 94
  • [10] Evaluation of recombinant factor VIII Fc (Eloctate) activity by thromboelastometry in a multicenter phase 3 clinical trial and correlation with bleeding phenotype
    Driessler, Frank
    Miguelino, Maricel G.
    Pierce, Glenn F.
    Peters, Robert T.
    Sommer, Jurg M.
    BLOOD COAGULATION & FIBRINOLYSIS, 2017, 28 (07) : 540 - 550
123